<DOC>
	<DOCNO>NCT00366457</DOCNO>
	<brief_summary>The main purpose study learn whether combination gemcitabine , bevacizumab erlotinib work treat patient advanced metastatic pancreatic cancer . Bevacizumab new anti-cancer drug . It antibody work slow stop cell growth cancerous tumor decrease blood supply tumor . It approve FDA treatment colorectal cancer still consider investigational treat pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine , Bevacizumab Erlotinib Pancreatic Cancer</brief_title>
	<detailed_description>- Participants receive study treatment outpatient . The study treatment give time period call cycle . Each treatment cycle 28 day . - Gemcitabine give intravenously day 1 , 8 , 15 ( per week first three week ) treatment cycle . - Bevacizumab give intravenously day 1 15 ( every 2 week ) treatment cycle . - Erlotinib take orally every day treatment cycle . - Participants see doctor nurse practitioner every week first 28 day treatment . During follow cycle , see doctor nurse practitioner day 1 day 15 cycle . - Each 4-week cycle repeat participant doctor decide remove study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Previously untreated patient unresectable metastatic adenocarcinoma pancreas ECOG Performance Status 02 18 year age old Radiographically measurable disease Expected survival least 4 month Creatinine &lt; /= 2.0 Adequate hepatic function Adequate hematopoietic function Use effective mean contraception subject childbearing potential Warfarin anticoagulation Prior treatment tyrosine kinase inhibitor , EGFR inhibitor , VEGF inhibitor Coexistent malignant disease Current recent ( within 4 week ) participation clinical trial Pregnancy Documented invasion adjacent organ major blood vessel Blood pressure &gt; 150/100mmHg Unstable angina NYHA Grade II great congestive heart failure History myocardial infarction stroke within 6 month Clinically significant peripheral vascular disease Evidence bleed diathesis coagulopathy Presence CNS brain metastasis Major surgical procedure , open biopsy , significant traumatic event within 28 day Minor surgical procedure , fine needle aspiration core biopsy within 7 day History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month Serious nonhealing wound , ulcer bone fracture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>